Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Reneo Pharmaceuticals Announces Pricing of Initial Public Offering

April 8, 2021
SAN DIEGO, CA - April 08, 2021 - Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial…

Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform

March 12, 2021
BOSTON, MA - March 12, 2021 - Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the closing of a…

Zosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDA

February 1, 2021
FREMONT, CA - February 01, 2021 - Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company completed its Type A meeting with the U.S. Food and…